12 results on '"Riello RJ 3rd"'
Search Results
2. Medicare Coverage and Patient Out-of-Pocket Costs for Cardiovascular-Kidney-Metabolic Medications.
- Author
-
Young GM, Bansal K, Riello RJ 3rd, Clark KAA, Dhruva SS, Faridi KF, and Desai NR
- Subjects
- Humans, United States, Male, Female, Aged, Cardiovascular Diseases economics, Cardiovascular Diseases drug therapy, Insurance Coverage economics, Insurance Coverage statistics & numerical data, Cardiovascular Agents economics, Cardiovascular Agents therapeutic use, Medicare economics, Health Expenditures statistics & numerical data
- Published
- 2024
- Full Text
- View/download PDF
3. Contemporary American and European Guidelines for Heart Failure Management: JACC: Heart Failure Guideline Comparison.
- Author
-
Ostrominski JW, DeFilippis EM, Bansal K, Riello RJ 3rd, Bozkurt B, Heidenreich PA, and Vaduganathan M
- Subjects
- Humans, Europe, United States, Cardiology, American Heart Association, Disease Management, Societies, Medical, Heart Failure therapy, Practice Guidelines as Topic
- Abstract
This review serves to compare contemporary clinical practice recommendations for the management of heart failure (HF), as codified in the 2021 European Society of Cardiology (ESC) guideline, the 2022 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) guideline, and the 2023 focused update of the 2021 ESC document. Overall, these guidelines aim to solidify significant advances throughout the HF continuum since the publication of previous full guideline iterations (2013 and 2016 for the ACC/AHA and ESC, respectively). All guidelines provide new recommendations for an increasingly complex landscape of HF care, with focus on primary HF prevention, HF stages, rapid initiation and optimization of evidence-based pharmacotherapies, overlapping cardiac and noncardiac comorbidities, device-based therapies, and management pathways for special groups of patients, including those with cardiac amyloidosis. Importantly, the ACC/AHA/HFSA document features special emphasis on HF risk prediction and screening, cost/value, social determinants of health, and health care disparities. The review discusses major similarities and differences between these recent guidelines and guideline updates, as well as their potential downstream implications for clinical care., Competing Interests: Funding Support and Author Disclosures Dr DeFilippis serves on a clinical trial committee for Abiomed and has had speaker engagements with AstraZeneca. Dr Riello has served as a consultant for Alexion AstraZeneca, Boehringer Ingelheim, Janssen, Johnson & Johnson, PhaseBio, and Portola. Dr Bozkurt has received personal fees from Vifor for serving on the steering committee for the Care HF Trial; has received personal fees from Amgen, AstraZeneca, and Baxter for serving on advisory committees or for consulting outside the submitted work; has received consulting fees from Bristol Myers Squibb, scPharmaceuticals, Baxter Healthcare Corporation, Sanofi Aventis, Relypsa, and Amgen; has served on the clinical event committee for the GUIDE HF Trial sponsored by Abbott Vascular; and has served on the data safety monitoring committee of the ANTHEM trial sponsored by LivaNova. Dr Vaduganathan has received research grant support from, has served on advisory boards of, or has had speaker engagements with American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; and has participated on clinical trial committees for studies sponsored by AstraZeneca, Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
4. Rationale, Design, and Patient Characteristics of a Cluster-Randomized Pragmatic Trial to Improve Mineralocorticoid Antagonist Use.
- Author
-
Clark KAA, Victoria-Castro AM, Ghazi L, Yamamoto Y, Coronel-Moreno C, Kadhim BA, Riello RJ 3rd, O'Connor K, Ahmad T, Wilson FP, and Desai NR
- Subjects
- Humans, Hyperkalemia epidemiology, Potassium blood, Stroke Volume, Heart Failure drug therapy, Mineralocorticoid Receptor Antagonists therapeutic use
- Abstract
Background: Despite robust evidence and strong guideline recommendations supporting use of mineralocorticoid receptor antagonists (MRAs) to improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF), these medications remain underused in clinical practice., Objectives: The goal is to determine if providing a tailored best practice alert (BPA) to outpatient providers suggesting guideline-recommended MRAs or information about available hyperkalemia treatment, if present, for patients with HFrEF will increase short-term MRA prescriptions., Methods: PROMPT-MRA (Pragmatic Trial of Messaging to Providers About Treatment With Mineralocorticoid Receptor Antagonists) is a pragmatic, cluster-randomized, controlled study. A total of 119 providers were randomized to receive a BPA or usual care. During an outpatient visit with participating providers, the BPA displayed recent laboratory test values and ejection fraction. The alert suggested guideline-recommended MRAs for eligible patients with a serum potassium of <5.0 mEq/L or novel potassium binders for those with a serum potassium of ≥5.0 mEq/L, each linked to an order set containing the corresponding medication and laboratory monitoring., Results: PROMPT-MRA completed enrollment with 1,210 patients. The primary outcome of PROMPT-MRA is to determine if a tailored BPA for outpatients with HFrEF will lead to higher MRA prescriptions 6 months following randomization compared with usual care. Secondary outcomes included incidence of hyperkalemia, use of novel potassium binders, heart failure hospitalizations, and mortality., Conclusions: If effective, the BPA can be scaled to improve population health outcomes with increased MRA prescribing among eligible patients with HFrEF, with or without a history of hyperkalemia. (Pragmatic Trial of Alerts for Use of Mineralocorticoid Receptor Antagonists [PROMPT-MRA]; NCT04903717)., Competing Interests: Funding Support and Author Disclosures PROMPT-MRA (Pragmatic Trial of Alerts for Use of Mineralocorticoid Receptor Antagonists; NCT04903717) was supported by CSL Vifor. Dr Riello has participated on Advisory Boards for Amgen, AstraZeneca, Boehringer Ingelheim, Janssen, Johnson and Johnson, Medicure, PhaseBio, Portola, and Salix; honoraria and consulting fees from Alexion, Amgen, AstraZeneca, Boehringer Ingelheim, Janssen, Johnson and Johnson, Pfizer, Portola, and Salix; and stock ownership in Akebia Therapeutics, Cytokinetics, Emergent BioSolutions, Iterum, Olema Pharmaceuticals, PhaseBio, and Verve Therapeutics. Dr Ahmad has received consulting fees from Sanofi, Amgen, and Cytokinetics; and has received research funding from Boehringer Ingelheim, AstraZeneca, Cytokinetics, and Relypsa. Dr Wilson has received grants R01DK11391, R01HS027626, and P30DK079310 and research support from AstraZeneca, CSL Vifor, and WHOOP. Dr Desai has worked under contract with the Centers for Medicare and Medicaid Services to develop and maintain performance measures used for public reporting and pay for performance programs; and has received research grants from and consulted for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Novartis, SCPharmaceuticals, and CSL Vifor. Drs Wilson and Desai are primary investigators of the ongoing PROMPT-MRA funded by CSL Vifor. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
5. Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial.
- Author
-
Ghazi L, O'Connor K, Yamamoto Y, Fuery M, Sen S, Samsky M, Riello RJ 3rd, Huang J, Olufade T, McDermott J, Inzucchi SE, Velazquez EJ, Wilson FP, Desai NR, and Ahmad T
- Subjects
- Humans, Hospitalization, Patient Discharge, Stroke Volume, United States, Heart Failure drug therapy
- Abstract
Acute Heart failure (AHF) is among the most frequent causes of hospitalization in the United States, contributing to substantial health care costs, morbidity, and mortality. Inpatient initiation of guideline-directed medical therapy (GDMT) is recommended for patients with heart failure with reduced ejection fraction (HFrEF) to reduce the risk of cardiovascular death or HF hospitalization. However, underutilization of GDMT prior to discharge is pervasive, representing a valuable missed opportunity to optimize evidence-based care. The PRagmatic Trial Of Messaging to Providers about Treatment of Acute Heart Failure tests the effectiveness of an electronic health record embedded clinical decision support system that informs providers during hospital management about indicated but not yet prescribed GDMT for eligible AHF patients with HFrEF. PRagmatic Trial Of Messaging to Providers about Treatment of Acute Heart Failureis an open-label, multicenter, pragmatic randomized controlled trial of 1,012 patients hospitalized with HFrEF. Eligible patients randomized to the intervention group are exposed to a tailored best practice advisory embedded within the electronic health record that alerts providers to prescribe omitted GDMT. The primary outcome is an increase in the proportion of additional GDMT medication classes prescribed at the time of discharge compared to those in the usual care arm., Competing Interests: Disclosures JH, TO, JM are employees of AstraZeneca. RJR is a consultant for Alexion, Amgen, AstraZeneca, Boehringer Ingelheim, Janssen, Johnson & Johnson, PhaseBio, and Portola. RD does executive teaching for Sanofi Consumer Health care. SEI has served on clinical trial committees and advisory boards for Boehringer Ingelheim, AstraZeneca, and Novo Nordisk. He has served as a consultant to Merck, Pfizer, Lexicon, vTv Therapeutics, Esperion and Abbott and has delivered lectures supported by Boehringer Ingelheim and AstraZeneca. TA is consultant for Sanofi-Aventis, Amgen, Cytokinetics. He has research funding from Boehringer Ingelheim, AstraZeneca, Cytokinetics, and Relypsa. NRD works under contract with the Centers for Medicare and Medicaid Services to develop and maintain performance measures used for public reporting and pay for performance programs. He reports research grants and consulting for Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Novartis, SCPharmaceuticals, and Vifor. The remaining authors have nothing to disclose., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
6. Adverse drug effects across patients with heart failure: a systematic review.
- Author
-
Butzner M, Riello RJ 3rd, Sarocco P, and Desai N
- Subjects
- Adrenergic beta-Antagonists adverse effects, Adult, Angiotensin Receptor Antagonists adverse effects, Angiotensin-Converting Enzyme Inhibitors adverse effects, Bradycardia chemically induced, Bradycardia drug therapy, Cough chemically induced, Cough drug therapy, Dizziness chemically induced, Dizziness drug therapy, Humans, Mineralocorticoid Receptor Antagonists adverse effects, Stroke Volume, Drug-Related Side Effects and Adverse Reactions epidemiology, Heart Failure drug therapy, Heart Failure epidemiology, Hyperkalemia chemically induced, Hyperkalemia drug therapy
- Abstract
Objectives: To summarize published literature on the incidence of adverse drug effects (ADEs) associated with guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF)., Study Design: Systematic literature review., Methods: A systematic literature review was conducted in PubMed, Ovid MEDLINE, and Clinical Key covering January 1990 to December 2018. Key search terms were ADEs for β-blockers (BBs), ACE inhibitors (ACEis), angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), and/or angiotensin receptor-neprilysin inhibitors (ARNis) in adult patients (≥ 18 years) with HFrEF., Results: A total of 279 eligible articles were identified, of which 29 reported drug-related adverse effects and were included in this review. Of the 29 studies, 11 examined BBs; 9, MRAs; 6, ARNis; 2, ACEis; and 1, ARBs. The most common reported ADEs across these therapeutic classes included bradycardia, dizziness, hypotension, hyperkalemia, cough, and renal impairment. The incidence of BB-induced bradycardia was 1% to 52% based on 9 studies, and 6 studies described dizziness as a result of BBs and ARNis (15%-43%). Fourteen studies reported induced hypotension (1.4%-63%); 13 studies, hyperkalemia (0.6%-30.2%); 3 studies, cough (37%-50%); and 4 studies, renal impairment (0.6%-7.6%)., Conclusions: Findings show that drug-related adverse effects are commonly reported in clinical trials and highlight the sizable burden of ADEs with medical therapy across patients with HFrEF. Additional real-world evidence and studies aiming to improve the tolerability of GDMT for patients with HFrEF are warranted.
- Published
- 2022
- Full Text
- View/download PDF
7. ARNI and MRA Combination in PARAGON-HF: Odd Couple or Dynamic Duo?
- Author
-
Riello RJ 3rd and Pitt B
- Subjects
- Angiotensin Receptor Antagonists, Humans, Stroke Volume, Heart Failure, Mineralocorticoid Receptor Antagonists
- Abstract
Competing Interests: Author Disclosures Dr. Riello has been a consultant for AstraZeneca, Janssen, Johnson & Johnson, and Portola; and has received a research grant from AstraZeneca. Dr. Pitt has been a consultant for Bayer, AstraZeneca, Sanofi/Lexicon, Boehringer Ingelheim, Relypsa/Vifor, KBP Pharmaceuticals, Sarfez, Cereno scientific, Phasebio, Tricida, SC Pharmaceuticals, SQ Innovations, and G3 Pharmaceuticals; has received stock options from Relypsa/Vifor, KBP Pharmaceuticals, Sarfez, Cereno scientific, Tricida, SC Pharmaceuticals, SQ Innovations, and G3 Pharmaceuticals; and has received U.S. Patent 9931412: site specific delivery of eplerenone to the myocardium, and U.S. provisional patent 63/045,784: Histone acetylation-modulating agents for the treatment and prevention of organ injury.
- Published
- 2021
- Full Text
- View/download PDF
8. Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and Outpatient Prescribing.
- Author
-
Harrigan JJ, Hubbard RA, Thomas S, Riello RJ 3rd, Bange E, Mamtani M, and Mamtani R
- Subjects
- Antirheumatic Agents therapeutic use, COVID-19, Coronavirus Infections epidemiology, Electronic Health Records trends, Humans, Pandemics, Pneumonia, Viral epidemiology, SARS-CoV-2, United States epidemiology, Ambulatory Care trends, Betacoronavirus, Coronavirus Infections drug therapy, Drug Prescriptions, Federal Government, Hydroxychloroquine therapeutic use, Pneumonia, Viral drug therapy
- Published
- 2020
- Full Text
- View/download PDF
9. Adoption of sacubitril-valsartan in the Medicare population.
- Author
-
Kahn PA, Riello RJ 3rd, Ahmad T, and Desai NR
- Subjects
- Aged, Biphenyl Compounds, Drug Combinations, Female, Humans, Male, Medicare, United States, Valsartan, Aminobutyrates therapeutic use, Heart Failure drug therapy, Tetrazoles therapeutic use
- Published
- 2020
- Full Text
- View/download PDF
10. Best practices for implementing venous thromboembolism prophylaxis across the continuum of care.
- Author
-
Dobesh PP, Ahuja T, Davis GA, Fatodu H, Francis WH, Hull FP, Johnson GL, Lenchus JD, Lenoir JG, McPherson C, Nemeth J, and Riello RJ 3rd
- Subjects
- Hospitalization, Humans, Risk Factors, United States, Anticoagulants therapeutic use, Benzamides therapeutic use, Factor Xa Inhibitors therapeutic use, Primary Prevention, Pyridines therapeutic use, Risk Assessment methods, Transitional Care standards, Venous Thromboembolism prevention & control
- Published
- 2018
11. Venous thromboembolism in acute medically ill patients: identifying unmet needs and weighing the value of prophylaxis.
- Author
-
Dobesh PP, Ahuja T, Davis GA, Fatodu H, Francis WH, Hull FP, Johnson GL, Lenchus JD, Lenoir JG, McPherson C, Nemeth J, and Riello RJ 3rd
- Subjects
- Acute Disease, Health Care Costs, Health Services Needs and Demand, Hospitalization, Humans, Risk Factors, United States epidemiology, Anticoagulants therapeutic use, Primary Prevention economics, Venous Thromboembolism epidemiology, Venous Thromboembolism prevention & control
- Published
- 2018
12. The use of betrixaban for extended prophylaxis of venous thromboembolism events in hospitalized, high-risk patients.
- Author
-
Dobesh PP, Ahuja T, Davis GA, Fatodu H, Francis WH, Hull FP, Johnson GL, Lenchus JD, Lenoir JG, McPherson C, Nemeth J, and Riello RJ 3rd
- Subjects
- Acute Disease, Aged, Benzamides administration & dosage, Factor Xa Inhibitors administration & dosage, Female, Health Care Costs, Hospitalization, Humans, Male, Pyridines administration & dosage, Randomized Controlled Trials as Topic, Risk Factors, United States epidemiology, Benzamides therapeutic use, Factor Xa Inhibitors therapeutic use, Primary Prevention, Pyridines therapeutic use, Venous Thromboembolism epidemiology, Venous Thromboembolism prevention & control
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.